Key Takeaways
- Manufacturing pivot delivers quality earnings: Gross margin expanded 750 bps to 60.8% as in-house manufactured reagents surged ~70%, shifting the mix decisively toward higher-margin domestic production.
- Installed base is the compounding engine: 2,500 cumulative instruments now anchor a razor-blade model; each analyzer generates ~INR3 lakhs in reagent revenue annually over an 8-10 year life, and reagent revenue grew 35% in FY26 on that base.
- FY27 growth ambition is aggressive: Management targets 30-35% topline growth, underpinned by 1,200+ new instrument placements, a 35% reagent revenue jump, and a 5x export surge excluding CDMO.
- CDMO is the emerging optionality: A European tech-transfer success on the Selectra Pro M has opened advanced-stage export negotiations; management expects INR10 crores in CDMO revenue in FY27 with 25%+ gross margins.
- What to watch next quarter: Whether the 30-35% growth target translates into actual instrument placements and reagent pull-through in Q1, the pace of Unit 4 capacity utilization, and any concrete CDMO contract signings.
The Manufacturing-Led Margin Inflection
- Gross margin jumped 750 bps YoY from 53.3% to 60.8%, driven by three reinforcing shifts: higher sales of manufactured reagents, an improved product mix favoring consumables over hardware, and better manufacturing efficiencies with operating leverage as volumes scaled.
- Manufactured reagents grew nearly 70% during FY26, validating the strategy of moving production in-house. Previously, 100% of reagents were imported; now most are manufactured indigenously, with imports continuing only where customer preference or government contracts require it. Import dependency is gradually reducing.
- Reagents now contribute nearly 70% of revenue, and management targets a steady-state mix of 65-68% consumables to 35-38% instruments. Instruments are the driving element and do not need high profitability; the blended margin on manufactured reagents is 60-65%, traded reagents ~50%, and instruments 15-20%.
- EBITDA grew 39% to INR98.1 cr, with margins improving from 22.5% to 28.7%. PAT more than doubled to INR55.7 cr, though FY25 was depressed by extraordinary and prior-period expenses, so the FY26 figure reflects a cleaner underlying earnings quality.
- FY27 margin outlook is cautiously optimistic: management expects EBITDA margins to remain slightly better than FY26 because of the 35-40% increase in manufactured reagent revenue, though the mix shift toward instruments for seeding could temper the expansion.
Ajay Mahanty: "Every new instrument installed creates a long-term opportunity for recurring reagent sale. This creates a razor-blade business model that help build visibility and sustainability in revenue."
Installed Base & The Razor-Blade Model
- 2,500 instruments now in the field: 1,550 Selectra Pro M clinical chemistry analyzers and 1,053 hematology analyzers were added by end-FY26. Each machine generates approximately INR25,000 in average monthly reagent revenue, or ~INR3 lakhs annually, translating to ~INR30 lakhs over a 10-year economic life.
- Instrument placements are the reagent flywheel: the company sells instruments to recover hardware investment and also places some on lease. The primary objective is not hardware margin but reagent pull-through; without analyzers, the reagent business cannot be driven.
- FY27 placement target is 2,000+ instruments including overseas markets, with 300-400 units specifically planned for the current financial year. Management expects 1,200-1,300 new installations annually across all instrument types as a normalized run-rate.
- Government MoU provided a capital-light boost: a contract to strengthen government laboratory systems required no upfront investment from Q-Line, as the government paid for the instruments. This adds to the installation base and secures 7-10 years of reagent revenue without the usual hardware recovery cycle. [10-11]
- H2 revenue de-grew 8.6% YoY because FY25 saw an exceptional, cyclic surge in instrument seeding. The dip is mechanical, not structural: reagent revenue grew 35% in FY26 precisely because of the prior year's placements, and the installed base continues to compound.
Ajay Mahanty: "Our main business objective is to get the more reagent business actually, not to put more number of not to sell hardware more, but of course both are you can say part and parcel. Without analyzer we cannot drive the reagent business."
FY27 Growth Roadmap
- Topline target of 30-35% growth rests on four legs: 35% reagent revenue growth from the expanding installed base, 2,000+ new instrument placements, a 5x jump in exports (excluding CDMO), and INR10 crores in first-year CDMO revenue with traction expected in Q3 and Q4.
- Unit 4, the new Lucknow manufacturing facility, was commissioned and capitalized in FY26. Phase-1 will shift all clinical chemistry reagents from the old Delhi facility; Phase-2 adds rapid molecular and other streams. Management expects to utilize 25-30% of Unit 4 capacity by end-FY27, and the facility can support 3-4x current revenue in reagents and CDMO over time, potentially by FY30.
- Export ambition is scaling fast: an international business manager has been appointed in Dubai, distribution partnerships are in place across several countries, and management sees significant opportunity across emerging markets for reliable, cost-effective diagnostic solutions. The 5x export growth target for FY27 excludes CDMO.
- No major capex is planned for the next two years: all growth capex for the next two-to-three years is already done. A CWIP plant (~INR15 crores) with basic structural work complete will serve as a warehouse for now, and may be developed as a fifth manufacturing unit if CDMO opportunities for large equipment materialize.
- The Delhi facility will scale production 6-7x over the next 2-3 years, as management believes the present facility cannot meet upcoming demand given qualification in multiple public procurement entities.
Ajay Mahanty: "In next 2 to 3 years definitely the quantity we are producing here at Delhi, I think it is not 3x, it will be at least 6x to 7x."
CDMO: The Emerging Export Optionality
- A successful tech transfer with a European company led to the re-engineering of the Selectra Pro M, a fully automated clinical chemistry analyzer. This gave Q-Line the confidence and capability to export back to the principal, and advanced-stage negotiations are underway for the principal to sell Q-Line-manufactured instruments across 55+ countries.
- FY27 CDMO revenue is pegged at INR10 crores, with traction expected in H2. Management describes this as the first true year of CDMO exports, and expects the stream to grow from there.
- CDMO gross margins are expected at 25%+, a meaningful step-up from the 10-15% gross margin retained on domestic instruments. The final margin depends on negotiation mastery with European partners.
- A parallel reagent CDMO window is opening: large European companies increasingly do not want to manufacture reagents themselves, creating an opportunity for Q-Line to supply them. Management intends to pursue this actively.
- Two or three additional instruments are expected from the tech-transfer route, and two or three from in-house product development, including the Microlab 300 semi-automatic analyzer, Medonic M20 hematology analyzer, and others in the pipeline.
Y.S. Prabhakara: "Margins will grow up by about 10 percentage points or so... about 10% to 15% we retain as gross margin in the domestic for the instruments, whereas that could be easily 25% plus we see depending upon how our negotiations we are able to master."
Product Pipeline & Market Positioning
- Selectra Pro M crossed 1,550 installations, with active reagent orders around 450 as of last financial year. The team is working to activate more installations in Community Health Centers and Primary Health Centers.
- An electrolyte analyzer was successfully commercialized during FY26, moving from an imported product to an indigenously designed, developed, and manufactured one.
- Six products were launched in the molecular segment in Q4 FY26, and the company has started receiving orders. R&D collaborations are active with three IIT incubation centers and the National Institute of Immunology incubation center.
- Q-Line deliberately avoids competing head-on with global players in high-automation track systems costing INR10 crore+. Instead, it focuses on stand-alone systems for labs running 30-400 tests per day, plus point-of-care products like rapid cards, glucometers, and Hb meters. Management calls this a disciplined, focused strategy rather than "hunky monkey jumping."
- The closed-system model covers 75-80% of business, where reagents are validated for Q-Line's own equipment. However, point-of-care products and screening programs for sickle cell, malaria, and STDs do not require lab-based devices, providing an open-system growth avenue. The company already supplies to NCDC, Government of India, and ICMR.
- R&D spend runs above INR2.5-3 crores annually, and the priority is reducing import dependency through technology collaboration. Semi-auto analyzer and hematology analyzer technology transfers are complete, with manufacturing shifting to India.
Saurabh Garg: "So, now we are very much focused and driving very focussedly to the market. We are not distracting jumping and hunky monkey jumping. So, we'll focus and we will do this type of way."
Balance Sheet, Governance & Concentration
- Receivable days are elevated because Q-Line sells instruments and recovers hardware cost, unlike the industry practice of placing instruments free of cost. Management expects working capital days around 100 and the receivable cycle within 90-120 days, and is now focusing on operating leverage and efficiency to manage this.
- Revenue shows high UP concentration because one large distributor based in Uttar Pradesh handles billing for government supplies across Bihar, West Bengal, Odisha, Haryana, and new states. This distributor is a related party (promoter entity) that runs labs for the government under a PPP model, providing turnkey solutions. Over 75 other distributors are normal entities.
- B2G concentration is 65% versus 35% trade. Management targets a 50-50 split by end-FY28, with CDMO and export success potentially accelerating the rebalancing.
- Corporate guarantees to related parties are being wound down. The company has informed various bankers and expects guarantees to become very minimal; management committed to not issuing any new corporate guarantees. However, when asked for a timeline, the CFO declined to provide one, saying she would need to get back on that.
- Governance upgrades are underway: an ERP implementation has been initiated across the organization, and PwC has been engaged to strengthen the internal control and governance framework.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 30-35% topline growth | FY27 |
| Reagent revenue growth | 35% increase, driven by installed base | FY27 |
| Instrument placements | 2,000+ new installations including overseas; 300-400 specifically planned | FY27 |
| Export growth | More than 5x (excluding CDMO) | FY27 |
| CDMO revenue | ~INR10 crores, traction in Q3/Q4 | FY27 |
| Unit 4 capacity utilization | 25-30% of capacity | End-FY27 |
| EBITDA margins | Slightly better than FY26 | FY27 |
| Working capital days | ~100 days | FY27 |
| Receivable cycle | Within 90-120 days | FY27 |
| B2G vs trade mix | 50-50 | End-FY28 |
| Unit 4 revenue scale | 3-4x of current revenue | By FY30 |
| Delhi production scale | 6-7x current quantity | Next 2-3 years |
| Capex | No major capex expected | Next 2 years |
| Corporate guarantees | No new guarantees; existing ones wound down to minimal | Ongoing (no timeline given) |
Key Metrics
| Metric | FY26 |
|---|---|
| Revenue from operations | ₹341.7 cr, +9% YoY |
| Gross margin | 60.8%, +750 bps YoY |
| EBITDA | ₹98.1 cr, +39% YoY |
| EBITDA margin | 28.7%, +620 bps YoY |
| PAT | ₹55.7 cr, vs ₹19.2 cr in FY25 |
| PAT margin | 16.3%, vs 6.1% in FY25 |
| Net worth | ~₹246 cr at end of FY26 |
| FY27 revenue growth guidance | 30% to 35% |
| Reagent revenue share | ~70% of total revenue |
| Reagent revenue growth | 35% in FY26 |
| Manufactured reagent sales growth | ~70% in FY26 |
| In-house manufacturing share (reagents) | 70% manufactured, 30% traded |
| Selectra Pro M cumulative installed base | >1,550 instruments |
| Total instruments added in last 2 years | 2,500 (1,550 Selectra Pro M + 1,053 hematology analyzers) |
| Total cumulative instrument base | 16,000–17,000 instruments |
| FY27 planned instrument additions | ~2,000 instruments |
| Export revenue | ~₹1.2 cr in FY26 |
| FY27 export growth target | >5x (excluding CDMO) |
| FY27 CDMO revenue target | ~₹10 cr |
| Revenue concentration (UP) | 77% of revenue |
| B2G vs trade revenue mix | 65% B2G, 35% trade |
| R&D spend | ~₹5 cr in FY26 |
| Receivable days | 134 days in FY26 |